Project Grant R35GM155301
- This $868,584 Project Grant, awarded September 1, 2025, by the National Institute of General Medical Sciences through its Biomedical Research and Research Training program (CFDA 93.859), supports fundamental research investigating how ribonucleic acid (RNA) modifications regulate adaptive messenger RNA (mRNA) translation. The University of Texas Health Science Center at Houston will conduct a two-year research initiative (through August 31, 2027) focused on elucidating the roles of TRMT1L, a...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training provides $454,805 to Kent State University to investigate the structural and sequence features required for recognizing RNA methylations and their role in post-transcriptional regulation of gene expression. The 3-year project aims to: 1) discover consensus sequences or structures for peptides that interact with N6-methyladenosine, 2) understand...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $440,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025 through May 31, 2030. This Maximizing Investigators' Research Award (MIRA) supports fundamental research investigating how the epitranscriptome—the collection of chemical modifications on RNA molecules—regulates...
- The University of Pennsylvania received a $443,806 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through June 30, 2030. This award supports fundamental research investigating the coordination and coregulation of enzyme-mediated chemical modifications across distinct ribonucleic acid (RNA) species, including messenger RNA (mRNA), transfer RNA (tRNA), and...
- Federal Grant Award Summary Northwestern University received a $440,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 3, 2026, with completion targeted for December 31, 2030. The award supports fundamental biomedical research investigating the role of messenger RNA (mRNA) internal 2-O methylation in post-transcriptional gene regulation. The research leverages...
- This Project Grant award of $442,750, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports fundamental research into the regulation of histone lysine methyltransferase (HLMT) substrates. Awarded to Virginia Polytechnic Institute & State University on August 1, 2025, with a completion date of June 30, 2030, the research addresses critical gaps in understanding how cells maintain epigenetic...
- Federal Grant Award Summary The University of Utah received a $423,500 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026, through January 31, 2031. This award supports fundamental research investigating the biological functions, biosynthesis, and dynamic regulation of RNA chemical modifications. The research addresses three key scientific challenges: identifying...
- The National Cancer Institute awarded a $922,755 Cooperative Agreement to the University of Massachusetts Medical School effective August 28, 2025, through July 31, 2030, under the Cancer Biology Research program (CFDA 93.396). The project will investigate tRNA (transfer RNA) modification reprogramming and translational remodeling in cancer, with a primary focus on melanoma progression and metastasis. The research will employ RNA mass spectrometry, sequencing approaches, and enhanced ribosome...
- This National Science Foundation (NSF) Biological Sciences program grant to Yale University, totaling $940,000 over 3 years beginning March 1, 2024, aims to systematically identify features of human and viral messenger RNAs (mRNAs) that regulate protein production. The project will employ a massively parallel reporter assay to quantify the impact of RNA modifications, structured RNA elements, and cell-specific factors on mRNA translation. Insights gained will provide a comprehensive...
- Federal Grant Award Summary The Trustees of Boston University received a Project Grant of $425,100 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded March 1, 2026, with a completion date of February 28, 2031. This Maximizing Investigators' Research Award (MIRA) supports the Kamenetska Lab's development of single-molecule biophysical tools and machine learning approaches to advance understanding of...
MOLECULAR MECHANISMS OF RNA METHYLTRANSFERASES. - PROJECT SUMMARY. THIS R35 MIRA APPLICATION CONCERNS INVESTIGATING THE STRUCTURE, FUNCTION, AND REGULATION OF TWO MRNA METHYLTRANSFERASE ENZYMES: RNA (GUANINE-N7) METHYLTRANSFERASE (RNMT) AND METTL3/METTL14. THE FIRST RNA MODIFICATION WAS IDENTIFIED IN THE EARLY 1950S WITH THE DISCOVERY OF PSEUDOURIDINE, FOLLOWED SOME YEARS LATER BY THE IDENTIFICATION OF N6-METHYLADENOSINE (M6A) AND N7-METHYLGUANOSINE (M7G) IN THE 1970S. SINCE THEN, OVER 150 RNA MODIFICATIONS HAVE BEEN DISCOVERED, WITH MANY MORE EXPECTED TO BE UNCOVERED AS MORE SENSITIVE AND BETTER TOOLS FOR THEIR IDENTIFICATION ARE DEVELOPED. AS THESE MODIFICATIONS EMERGE, RESEARCHERS WILL NEED TO UNCOVER THE PROTEIN MACHINERY THAT WRITES AND ERASES THESE MARKS, DETERMINE THEIR BIOLOGICAL FUNCTIONS, AND DISCERN HOW THEY ARE REGULATED. DEFECTS IN THE RNA MODIFICATIONS MAY LEAD TO DISEASES SUCH AS CANCER, CARDIOVASCULAR ABNORMALITIES, VIRAL PATHOGENESIS, OR COGNITIVE IMPAIRMENT. THEREFORE, UNDERSTANDING THE "CODE" AND THE ENZYMATIC PROCESSES THAT GOVERN THE PRESENCE OF RNA MODIFICATIONS ARE KEY TO REVEALING PATHOPHYSIOLOGICAL MECHANISMS AND THE DEVELOPMENT OF NOVEL THERAPEUTICS. THE OVERALL GOAL OF OUR RESEARCH PROGRAM IS TO UNDERSTAND THE MOLECULAR MECHANISMS FOR HOW POST-TRANSLATIONAL MODIFICATIONS REGULATE THE READERS, WRITERS, AND ERASERS OF RNA MODIFICATIONS, HOW THESE MARKS IMPACT GENE EXPRESSION, AND HOW DEFECTS IN THIS SYSTEM CONTRIBUTE TO DISEASE. MANY READERS, WRITERS, AND ERASERS OF RNA MODIFICATIONS HARBOR PTMS, BUT OUR UNDERSTANDING OF THEIR INFLUENCE ON PROTEIN FUNCTION IS VERY LIMITED. THEREFORE, WE WILL USE A COMBINATION OF PROTEIN SEMI-SYNTHESIS, ENZYMOLOGY, STRUCTURAL BIOLOGY, MASS SPECTROMETRY, AND CELL BIOLOGY STRATEGIES TO UNRAVEL THESE NOVEL REGULATORY MECHANISMS. IN THE NEXT FIVE YEARS, WE PLAN TO INVESTIGATE THE MECHANISTIC BASIS FOR HOW RNMT AND THE METTL3/METTL14 COMPLEX ARE REGULATED BY PTMS, WITH A LONG-TERM VISION OF EXPANDING TO OTHER READERS, WRITERS, AND ERASERS IN THIS FAMILY. RNMT CATALYZES THE METHYLATION OF THE 5'CAP OF RNA, WHICH IS ESSENTIAL FOR TRANSCRIPT STABILITY, SPLICING, NUCLEAR TRANSPORT, AND CAP-DEPENDENT TRANSLATION. RNMT AND ITS INTERACTING PARTNER, RAM, ARE PHOSPHORYLATED AND UBIQUITINATED; HOWEVER, THE MOLECULAR AND STRUCTURAL DETAILS FOR THEIR REGULATION AND IMPACT ON BIOLOGY ARE NOT WELL UNDERSTOOD. THE METTL3/METTL14 COMPLEX METHYLATES MRNA TO GENERATE N6-METHYLADENOSINE, WHICH INFLUENCES TRANSCRIPT PROCESSING, STABILITY, TRANSLATION, AND LOCALIZATION. THE METTL3/METTL14 COMPLEX IS REGULATED BY ARGININE METHYLATION AND UBIQUITINATION; HOWEVER, VERY LITTLE IS KNOWN ABOUT HOW THEY IMPACT THE COMPLEX'S BIOCHEMICAL AND BIOLOGICAL BEHAVIOR. THEREFORE, WE PLAN TO ASSESS THE MECHANISTIC AND STRUCTURAL BASIS FOR HOW THESE MODIFICATIONS REGULATE THEIR BIOCHEMICAL AND CELLULAR FUNCTIONS USING PROTEIN SEMI-SYNTHESIS. FURTHERMORE, WE PLAN TO CHARACTERIZE THE UBIQUITIN E3 LIGASES THAT TARGET THESE PROTEINS FOR DEGRADATION AND DEUBIQUITINASES THAT REVERSE THIS PROCESS. SUCCESSFUL COMPLETION OF THESE PROJECTS WILL PROVIDE THE MOLECULAR UNDERPINNING FOR HOW THESE RNA-MODIFYING ENZYMES ARE REGULATED BY PTMS AND INFORM FUTURE THERAPEUTIC INTERVENTIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $412.5k | 6/13/25 | ||
| Not listed | $246.5k | 6/14/24 | ||
| Not listed | $246.5k | 6/14/24 |